What the FDA labels say about taking them together
Everolimus and maribavir
Maribavir's FDA label of January 27, 2026 names everolimus in its drug interactions section; the everolimus labels PlainMeds reads (2) do not name maribavir. The maribavir label: “Frequently monitor everolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the maribavir FDA label on DailyMed (effective January 27, 2026, Takeda Pharmaceuticals America, Inc.).
What does the everolimus label say about maribavir?
Everolimus's label (effective June 1, 2026) and its 1 other brand-application label do not name maribavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the maribavir label say about everolimus?
Maribavir label, drug interactionsConcomitant Drug Class/Drug Name: Everolimus; Effect on Concentration: ↑ Everolimus; Clinical Comments: Frequently monitor everolimus levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust dose, as needed.
Maribavir label, warnings and precautionsSome maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir. ( 5.2 , 12.4 , 14.1 ) The concomitant use of LIVTENCITY and certain drugs may result in potentially significant drug interactions, some of which may lead to reduced therapeutic effect of LIVTENCITY or adverse reactions of concomitant drugs. ( 5.1 , 5.3 , 7.1 , 7.2 , 7.3 ) LIVTENCITY has the potential to increase the drug concentrations of certain immunosuppressant drugs where minimal concentration changes may lead to serious adverse events (including tacrolimus, cyclosporine, sirolimus and everolimus).
Source: FDA drug label (Livtencity), Takeda Pharmaceuticals America, Inc., effective January 27, 2026 (SPL set c94fc2c5-e840-4f18-b7d8-d5eacb26d3a0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Maribavir | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | n/a |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once